Seres Therapeutics Inc.

09/29/2021 | Press release | Distributed by Public on 09/29/2021 12:02

Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection